---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-200739"
form_type: "8-K"
ticker: "RNTX"
cik: "0001420565"
company_name: "Rein Therapeutics, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:17:21.381564+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF

## Summary
- Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
- Cash $21.9M as of June 30, 2024; raised $18.2M net from May 2024 registered direct offering.
- Cohort 1 of Phase 1b LTI-03 (2.5 mg BID) showed positive trends in 7 of 8 biomarkers with statistical significance in 3 fibrosis-related biomarkers.
- LTI-03 was generally well-tolerated; topline results from high-dose Cohort 2 expected in Q3 2024.
- Company expects cash to fund operations into second half of 2025.

## SEC filing metadata
- accession: 0001193125-24-200739
- form_type: 8-K
- ticker: RNTX
- cik: 0001420565
- company_name: Rein Therapeutics, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/0001193125-24-200739-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1420565/000119312524200739/d882513d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-200739
- JSON: https://secwatch.observer/filing/0001193125-24-200739.json
- Plain text: https://secwatch.observer/filing/0001193125-24-200739.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.